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Abstract
       Somatostatin (SS) is an inhibitory hormone/transmitter of the secretory and proliferative responses of the
widely spread target cells. SS exerts its effects via a family of G-protein-coupled receptors termed SSR1-5.
SSR2 are one of the most frequently found receptors in normal cells and in neuroendocrine tumour cells.
Owing to alternative splicing, SSR2 exist in two variants with the same binding capacity; a shorter (SSR2(b))
and a longer (SSR2(a)) variant. SSR2(a) is much more expressed than SSR2(b). Also, SSR2(a) is involved in
both physiological and pathophysiological processes, which makes it of interest to study. In this thesis the
expression and intracellular distribution of this receptor were investigated using tumour scintigraphy and
RPA, as well as biochemical and immunocytochemical methods including Western blot and confocal laser
scanning microscopy. Different cell types of neuroendocrine (NE) origin or emanating from the
neuroectoderm were studied. 
Human NE tumours midgut carcinoid (MC) and medullary thyroid tumour (MTC), and, for comparison,
breast carcinoma (BC) were studied using RPA and 111In-DTPA-D-Phe1-octreotide scintigraphy. SSR2(a)
mRNA values were higher in MC, followed by MTC and BC, in accordance with the results (T/B values)
from tumour scintigraphy using 111In-octreotide scintigraphy. The high receptor mRNA values and T/B
values were positively correlated in MC, suggesting SSR2(a) as the main receptor subtype responsible for
binding and uptake of the SS analogue in this tumour.
        The human PNS-derived neuroblastoma cell line SH-SY5Y was studied in tissue culture. After neuronal
differentiation, initiated by treatment with retinoic acid (RA), the SSR2(a) was  affiliated with the plasma
membrane, the cytoplasm and processes.The number of SSR2(a)-positive cells and SSR2(a)-IR were markedly
increased by RA treatment, but only minor increases in the receptor mRNA values were seen. After RA
treatment, catecholaminergic markers (TH, VMAT2, NPY) were decreased whereas the cholinergic markers
(ChAT, VAChT, VIP) were increased. On the other hand, the integral synaptic vesicle membrane proteins
p38-IR and SV2-IR were not markedly affected by the treatment. SS was present not only in the cytoplasm,
but also in the nucleus, and more strongly so after the treatment. The presence of both the receptor and its
ligand in the same cells may suggest that SH-SY5Y cells exhibit autocrine regulation via this receptor/ligand
system. The neuronal differentiated SH-SY5Y cells may thus be used as a model for studying turnover and
transport of SSR2(a) receptor in cells/neurons.
        The CNS-derived mouse CAD cell line was studied in vitro. Neuronal differentiation, with rounded cell
bodies and extension of very long neurite-like processes, was induced into this cell line after protein starvation
(PFM). The SSR2(a) was affiliated with the plasma membrane and the cytoplasm, concentrated in the
perinuclear zone (Golgi area), both in the presence (SCM) and the absence of serum (PFM). In differentiated
CAD cells SSR2(a)-IR was found to be partially shifted into the long processes and markedly increased. CAD
cells were positive for catecholaminergic markers (TH, PNMT, VMAT2, NPY) which were shifted into the
processes after protein withdrawal. In contrast, cholinergic markers (ChAT, VAChT) were not observed in the
cells. However, VIP-IR was present in the cytoplasm in SCM cultures concentrated into the perinuclear zone.
After differentiation, VIP-IR was enhanced and partially shifted into the processes. Similar distribution of
p38-IR and SV2-IR were seen in the cells. The marker for neuronal development and regeneration (GAP-43)
was, after protein withdrawal, strongly upregulated and shifted into the processes, concentrated particularly in
the distal growth cone-like swellings. CAD cells were SS-positive and showed higher SS-IR in protein
starved cultures. The presence of both the receptor and its ligand in the same cells may suggest that CAD cells
exhibit autocrine regulation via this receptor/ligand system. Protein-starved CAD cells may constitute an
excellent model for studying the turnover and intracellular dynamics of the SSR2(a) receptor and other
substances.
      In rat hypothalamus, ependymal cells and tanycytes of the third ventricle were studied. In tanycytes
SSR2(a)-IR was present and could be traced from the luminal processes all the way to the capillary plexus of
the median eminence (ME). Many of the SSR2(a)-positive tanycytes were also vimentin-positive, but few
contained GFAP-IR. The location of S-100-IR was mainly confined to the apical tips of the tanycytes, and to
the ependyma of the third ventricle. Since high levels of SS have been found in the CSF of the third ventricle,
it is suggested that SS via SSR2(a) receptor may regulate the physiology of tanycytes and possibly of the
adenohypophysis, thereby influencing NE mechanisms.
       The thesis demonstrates the presence of SSR2(a) expression in four different cell types, suggesting that
this receptor is of general physiological importance, In addition, several pathophysiological conditions may be
influenced by this receptor and its ligands. Two new observations are reported: 1) The presence of SS in the
nuclei of cultured SH-SY5Y cells, enhanced after RA-induced differentiation, which indicates that SS may
serve as a transcription factor like many other smaller peptides. 2) The strong presence of the receptor protein
in ependyma and tanycytes of the third ventricle, which may be influenced by the physiological levels of CSF-
SS demonstrated by previous investigators.
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